Working alongside global lead counsel Gleiss Lutz, as well as Simpson Thacher & Bartlett and Reed Smith, a number of law firms across CEE advised Panasonic Healthcare Holdings Co., Ltd. (“Panasonic”) in its acquisition of Bayer AG’s Diabetes Care business. Hengeler Mueller advised Bayer on the deal, which was carried out in 43 jurisdictions, for a total consideration around EUR 1 billion. Panasonic is backed by funds sponsored by leading global investment firm KKR and the Panasonic Corporation.
Bayer’s Diabetes Care business accounted for EUR 909 million in sales in 2014. With Panasonic, the newly-acquired Diabetes Care business will operate as a stand-alone company named Ascensia Diabetes Care. Together Ascensia Diabetes Care and Panasonic Healthcare will develop, manufacture, market, and sell blood glucose monitoring meters and strips for people with diabetes in more than 125 countries. Following the close of the transaction in all countries, Ascensia Diabetes Care will have 1,400 employees and operations in 38 countries.
In Poland, WKB Wiercinski, Kwiecinski, Baehr advised Panasonic on Polish legal aspects of the acquisition. According to WKB, “within the Polish part of the transaction, Panasonic Healthcare’s subsidiary Ascensia Diabetes Care Poland sp. z o.o. acquired directly from Bayer Polska sp. z o.o. (Bayer’s subsidiary) assets including, among other things, a portfolio of medical devices.” WKB advised Panasonic Healthcare and Ascensia DC Poland throughout the entire process on all Polish legal aspects of the transaction, including transaction documents and advice with respect to the regulations on, and refunds for, medical devices, financing, labor law, real estate law, and environmental protection law, as well as corporate and personal data protection matters. The WKB team was coordinated by Partner Pawel Hincz, who was supported by Senior Associate Juliusz Krzyzanowski, Partners Ben Davey and Jakub Jedrzejak, Counsels Izabela Szczygielska and Sergiusz Urban, Senior Associates Piotr Grabarczyk, Sylwia Czerwik-Drozdowicz, and Anna Wojciechowska, and Associate Katarzyna Syska.
Wolf Theiss advised Panasonic on Austrian and Slovenian aspects of the deal. The Wolf Theiss team was led by Lead Partner Eva Fischer, supported in Austria by Partner Kurt Retter, Senior Associates Barbara Jakubowics and Walter Poschl, and Associates Johanna Freudensprung, Mario Laimgruber, and Rainer Kammerhofer. The Wolf Theiss team in Slovenia consisted of Partner Laura Struc, Senior Associate Teja Balazic, and Associates Ziga Dolhar and Neja Nastran.
In Russia, Panasonic was advised by a Herbert Smith Freehills team consisting of Lead Corporate Associate Lena Ivanova, Partners Evgeny Zelensky, Vladimir Melnikov, and Artjom Buligin, Senior Associate Evgeny Yuriev, Associates Arina Fot and Victor Rogachev, and Trainee Dmitry Mazurov.
Panasonic was advised on Turkish matters by a team from Paksoy consisting of Lead Partner Serdar Paksoy and Senior Associate Serdar Ildirar.
Panasonic was advised on Greek aspects by a team from the Zepos & Yannopoulos firm coordinated by Partner George Siganidis, and consisting of Attorneys Stefanos Charaktiniotis, Rania Papakonstantinou, Dafni Cozonis, Yannis Kantartzis (who also acted as interim CEO of Ascensia Greece), Julia Pournara, and Anastassia Makri.
In Lithuania, Panasonic was advised by a team from Cobalt led by Managing Associate Maksimas Saveljevas.
When contacted by CEE Legal Matters for the identity of CEE firms advising it on the deal, a Bayer spokesman confirmed only that Hengeler Mueller was its global lead counsel on the deal, but said that “we would not like to go in more detail as in many countries there were only minor tasks to do.”
